CONMED (CNMD) Earnings Date & Reports

Key Takeaways

• Third-quarter 2026 net sales came in at $335.6 million, down 0.7% year over year and slightly below the consensus estimate of about $336.3 million.
• Adjusted diluted earnings per share (EPS) reached $1.04, beating the consensus estimate of $1.00 but down 3.2% from $1.08 in the prior-year quarter.
• GAAP (Generally Accepted Accounting Principles) diluted EPS jumped to $0.66 from $0.09 a year earlier, as the prior-year period carried heavy charges.
• Organic constant-currency sales rose 6.7%, excluding the strategic exit of gastroenterology (GI) product offerings.
• Domestic sales fell 11.0%, while international sales climbed 13.1%, reflecting mixed demand across regions.
• CONMED raised its full-year 2026 adjusted diluted EPS guidance to a range of $4.54 to $4.61.
• For more detail, explore CONMED's Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
• Looking for trade ideas? Discover Trending AI Robots to explore AI-driven market signals.

Earnings Context and Why It Matters

CONMED Corporation (NYSE: CNMD) is a medical technology company supplying surgical devices across orthopedics, general surgery, gynecology, and thoracic surgery. Its third-quarter report matters because the company is navigating a portfolio transition: it has exited certain gastroenterology product lines to refocus on higher-growth platforms such as AirSeal, Buffalo Filter, and BioBrace. As a result, reported sales growth is being weighed down by deliberate divestitures even as the underlying, or "organic," business continues to expand. Investors are watching whether that underlying momentum can offset revenue lost to strategic exits, and whether margin and interest-expense trends can sustain earnings growth. The report offers a key checkpoint on both the company's restructuring progress and its profit trajectory heading into year-end.

Reported Results

For the third quarter ended September 30, 2026, CONMED reported net sales of $335.6 million, a 0.7% decline from the prior-year period and slightly below the consensus estimate of approximately $336.3 million. On an organic constant-currency basis, net sales increased 6.7%, excluding the impact of strategic exits from gastroenterology product offerings.

GAAP net income rose to $19.8 million, up from $2.9 million a year earlier, while GAAP diluted EPS climbed to $0.66 from $0.09. Adjusted diluted EPS came in at $1.04, exceeding the consensus estimate of $1.00 but down from $1.08 in the same period last year, reflecting higher adjusted interest expense.

By segment, Orthopedic Surgery sales grew 7.7% to $148.8 million, while General Surgery sales declined 6.5% to $186.7 million. Domestic sales fell 11.0%, whereas international sales increased 13.1%. The company also updated full-year 2026 guidance, raising adjusted diluted EPS expectations to $4.54–$4.61 and narrowing net sales guidance to $1.360 billion–$1.366 billion.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market more efficiently. It scans thousands of stocks and ETFs using customizable criteria such as industry, market capitalization, technical indicators, price patterns, volatility, and performance metrics. By combining fundamentals, trends, and AI-driven signals, the screener helps surface trade ideas, trending stocks, breakout candidates, and emerging market opportunities that manual screening might miss. Whether you are tracking healthcare names like CONMED or searching across sectors, the AI Screener streamlines the research process. Explore the AI Screener to build your own watchlists and uncover potential opportunities.

Market Reaction and Investor Sentiment

Heading into the report, the stock traded with some caution, with shares down modestly during the session ahead of the after-market release. The headline result was mixed: adjusted EPS of $1.04 beat the consensus estimate by $0.04, but reported revenue came in slightly below expectations as the GI divestitures continued to pressure the top line. Investors are likely to focus on the divergence between reported and organic growth, as well as the company's decision to raise full-year adjusted EPS guidance. The lift in guidance, paired with sustained organic growth, signals confidence in the company's core franchises even as reported figures lag. Key risks include continued domestic softness, higher interest costs, and the pace of hospital capital spending.

Forward Outlook and Key Factors to Monitor

Following this quarter, investors should watch how CONMED's underlying growth platforms perform as it completes its portfolio transition. Management continues to emphasize AirSeal, Buffalo Filter, and BioBrace as long-term growth drivers, and their adoption trends will be central to whether organic growth can offset the revenue lost from exiting gastroenterology products.

Margin dynamics also deserve close attention. Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) rose modestly in the quarter, but higher adjusted interest expense pressured adjusted EPS. Monitoring the company's debt levels and refinancing activity will be important, since financing costs directly influence the bottom line.

On the demand side, domestic sales weakness remains a notable headwind, while international strength has provided an offset. Investors should track hospital capital budgets and elective procedure volumes, which can influence both General Surgery and Orthopedic Surgery results. Finally, the company's updated full-year guidance implies continued divergence between reported and organic growth, so clarity on strategic exits and any further portfolio actions will help shape expectations for 2027.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations